Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TVB-3567

Small molecule · developed by Sagimet Biosciences

Phase 1 Most advanced trial
SGMT Developer
1 Registered trials

What is TVB-3567?

TVB-3567 is an orally administered capsule studied in acne vulgaris.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Dermatology
Developer
Sagimet Biosciences Inc. (SGMT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06989840 Phase 1 Acne Recruiting SGMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acne

More from Sagimet Biosciences

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SGMT page.

Follow SGMT, the company behind TVB-3567

See SGMT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SGMT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.